PCM
IMVT icon

Prelude Capital Management’s Immunovant IMVT Stock Holding History

Prelude Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,683
Closed -$1.06M – 1391
2025
Q4 		$1.06M Hold
41,683
– – 0.08% 286
2025
Q3 		$672K Buy
+41,683
New +$675K 0.05% 418

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Prelude Capital Management's IMVT Position: Q1 2026 in Review

Prelude Capital Management sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 41,683 shares — an estimated $1.06M sold.

Prelude Capital Management first reported a position in IMVT in Q3 2025 and held it in 2 quarters. The position peaked at $1.06M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Prelude Capital Management reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 41,683 Immunovant shares in Q1 2026, an estimated $1.06M.
  • Prelude Capital Management first reported a position in Immunovant in Q3 2025 and held it in 2 quarters.
  • Prelude Capital Management's Immunovant position peaked at $1.06M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.